Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study.

Autor:	Chapchap EC; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Kerbauy LN; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Esteves I; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Belucci TR; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Rodrigues M; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Kerbauy FR; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., de Souza Santos FP; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Ribeiro AAF; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Hamerschlak N; Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	European journal of cancer care [Eur J Cancer Care (Engl)] 2019 Sep; Vol. 28 (5), pp. e13122. Date of Electronic Publication: 2019 Jun 30.
DOI:	10.1111/ecc.13122
Abstrakt:	Objectives: To analyse clinical outcomes comparing two age groups of patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT), and to identify risk factors associated with older patients' mortality. Methods: In this retrospective study, the medical charts of all consecutive patients admitted in one hospital for allo-HSCT were reviewed. Overall survival (OS) and other outcomes were compared between patients aged up to 55 years (YG) and older than 55 (EG). Results: From January 2007 to August 2014, 111 adult patients were admitted for allo-HSCT and were included 75 in the YG and 36 in the EG group. The OS rate at D+ 100 was 84% for YG individuals in contrast to 75% in the EG (p = 0.01), and 71% vs. 50% at one year after HSCT (p = 0.01) respectively. Therapy-related mortality (TRM) rates for the YG and EG were, respectively, 14% vs. 17% (p = 0.04) at D+ 100 and 17% vs. 32% (p = 0.04) at one year. Haploidentical donor type and active disease status significantly increased mortality risk in the EG (hazard ratio 2.42; p = 0.018; and 2.04; p = 0.033). Conclusion: YG and EG have similar TRM rates early after allo-HSCT, but the elderly had higher TRM during the critical period from 100 days to one year. (© 2019 John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu